INDV Earnings

INDV reported its earnings on 2026-02-26, showcasing a revenue of against an estimate of 305.23M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.65 by 0%. The stock experienced a 0.24% price change on the earnings day and a -8.21% change over the next five days, reflecting market reactions to the results.

Following INDV's earnings announcement on 2026-02-26, the stock price moved by 0.24% on the day of the release. Over the subsequent five days, it saw a -8.21% change. Historically, INDV's stock price tends to shift by an average of -3.59% in the 10 days leading up to earnings and 4.3% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate INDV's annual revenue to reach 306.22M, while the EPS is projected at 0.68. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between INDV's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, INDV's stock price typically moves by -3.59% in the 10 days before its earnings and 4.3% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.68 and revenue of 306.22M.

Indivior's earnings call highlights strong financial performance, with SUBLOCADE revenue growth and improved cash flow, despite a significant DOJ payment. Optimistic guidance for 2025 and a focus on shareholder returns through share repurchases are positive indicators. While management avoided some specifics, the overall sentiment in the Q&A was positive, with analysts recognizing growth potential in LAI buprenorphine penetration. The company's strategic focus on new therapeutic areas and operational efficiencies further supports a positive outlook. Given the market cap, the stock is likely to see a positive reaction, estimated between 2% to 8%.